Non-pharmacological interventions to improve the patient experience of colonoscopy under moderate or no sedation: a systematic review protocol

Colin Sue-Chue-Lam, Matthew Castelo, Jill Tinmouth, Diego Llovet, Teruko Kishibe, Nancy N Baxter

ABSTRACT

Introduction The patient experience is a critical dimension of colonoscopy quality. Sedative and analgesic drugs are commonly used to improve the patient experience of colonoscopy, with predominant regimens being deep sedation, typically achieved with propofol, and moderate sedation, typically achieved with an opioid and a benzodiazepine. However, non-pharmacological interventions exist that may be used to improve patient experience. Furthermore, by identifying non-pharmacological interventions to increase the quality of patient experience under moderate sedation, jurisdictions facing rising use of deep sedation for colonoscopy and its significant associated costs may be better able to encourage patients and clinicians to adopt moderate sedation. Advancing either of these aims requires synthesising the evidence and raising awareness around these non-pharmacological interventions to improve the patient experience of colonoscopy.

Methods and analysis A systematic review will be conducted that searches multiple electronic databases from inception until 2020 to identify randomised controlled trials evaluating what, if any, non-pharmacological interventions are effective compared with placebo or usual care for improving the patient experience of routine colonoscopy under moderate or no sedation. Two reviewers will independently perform a three-stage screening process and extract all study data using piloted forms. Study quality will be assessed using the Cochrane Risk of Bias Tool V.2.0. Where multiple studies evaluate a single intervention, evidence will be quantitatively synthesised using pairwise meta-analysis, otherwise narrative synthesises will be undertaken.

Ethics and dissemination This is a review of existing literature not requiring ethics approval. The review findings will be included in future efforts to develop an implementation strategy to reduce the use of deep sedation for routine colonoscopy. They will also be published in a peer-reviewed journal, presented at conferences and contribute to a doctoral thesis.

INTRODUCTION

Across the USA and Canada, outpatient, low-risk (‘routine’) colonoscopy is increasingly being performed under ‘deep sedation’ with propofol rather than ‘moderate sedation’ with opioids and benzodiazepines. It is clear that patient experience is an important dimension of colonoscopy quality, that sedation improves patient experience and colonoscopy effectiveness, and that deep sedation may be particularly valuable for prolonged procedures, emergency procedures and patients with complex needs. However, it is less clear that deep sedation delivers comparable value to moderate sedation for routine colonoscopy when this strategy costs over 40% more than moderate sedation. It is less clear that deep sedation delivers comparable value to moderate sedation for routine colonoscopy when this strategy costs over 40% more than moderate sedation. Despite the added cost, deep sedation does not provide significantly improved safety, effectiveness or efficiency for routine colonoscopy. Addressing the appropriate use of deep sedation for routine colonoscopy will require additional research directed at addressing barriers to change.

Though both moderate and deep sedation provide an excellent patient experience, deep sedation provides a small increase in patient satisfaction, and patients and providers who highly value this may resist...
efforts to encourage judicious use of deep sedation. This may happen by two mechanisms: patients may themselves desire deep sedation, and clinicians may perceive patients to desire deep sedation. Strategies to reduce the use of deep sedation that fail to acknowledge both of these factors may be ineffective or, worse, harmful by deterring those who would benefit from colonoscopy from undergoing the procedure.\(^3\) For jurisdictions where deep sedation is uncommon, clinicians should nonetheless be striving to maximise the quality of the patient experience of colonoscopy, and they stand to benefit from evidence to support efforts to do so.

Fortunately, non-pharmacological interventions to improve the patient experience exist. Such interventions include preprocedural information, altering the patient’s starting position, water exchange colonoscopy, audio and/or visual distraction and use of an ultrathin colonoscope.\(^4\) However, the breadth and effectiveness of these non-pharmacological interventions are not well described in the existing literature. The British Society of Gastroenterology’s position statement on patient experience during gastrointestinal (GI) endoscopy affirms not only patient experience as a core dimension of health-care quality but also enumerates few options available to endoscopists to alter the patient experience during GI endoscopy.\(^5\) To inform efforts to improve the patient experience of colonoscopy and potentially reduce the use of deep sedation for routine colonoscopy, additional research is needed.

To address this knowledge gap, we will conduct a systematic review to identify and synthesise the existing literature describing non-pharmacological interventions to improve the patient experience of colonoscopy.

METHODS AND ANALYSIS

This systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) statement.\(^6\) This review was prospectively registered in PROSPERO and will be reported in accordance with the PRISMA statement.\(^7\) Significant amendments to this protocol will be reported.

Patient and public involvement

Patients and the public were not involved in the design, conduct or reporting of this study. Results of the systematic review will be disseminated to patients and the public through relevant conferences, peer-reviewed publications and social media.

Identifying the research question

The research question was identified in consultation with clinicians and researchers with expertise in colonoscopy and a preliminary literature search. The research question is as follows: what (if any) non-pharmacological interventions are effective compared with placebo or usual care for improving the patient experience with routine colonoscopy under no or moderate sedation?

Eligibility criteria

Peer-reviewed publications in English of randomised controlled trials will be eligible for inclusion. Studies, including adults >18 years old evaluating the effectiveness of any non-pharmacological intervention (given within 1 week of the date of colonoscopy) compared with placebo or usual care for improving the patient experience of colonoscopy (measured within 24 hours of discharge from the endoscopy suite) under moderate or no sedation will be included.

Exclusion criteria

Due to resource constraints, we will exclude studies published in languages other than English. This practice is unlikely to introduce bias.\(^8\) We will exclude studies of non-elective colonoscopies and colonoscopies in patients admitted to hospital if these are the only patients who were randomised. Studies not reporting any outcomes of interest will also be excluded.

We anticipate that our broad search will identify a large number of publications and have planned a threestage screening process to address this. Two independent reviewers will conduct a title screen, followed by an abstract screen and finally a full-text screen using piloted forms on the DistillerSR platform (Evidence Partners, Ottawa, Canada). Disagreements will be resolved through discussion and consensus, involving a third reviewer if necessary.

Information sources

A search strategy will be designed with assistance from an expert information specialist. The search strategy will be reviewed using the Peer Review of Electronic Search Strategies checklist.\(^9\) The search terms include variations on terms for ‘Colonoscopy’ and ‘Patient Comfort’ (online supplemental file). MEDLINE, Embase, CINAHL, PsycINFO, Scopus and the Cochrane Central Register of Controlled Trials will be searched for publications from inception until 2020, with an additional search prior to publication. In addition to these databases, reference lists of included articles, reference lists of relevant systematic reviews, clinicaltrials.gov, a PubMed Related Article search and OpenGrey will be searched.

Data extraction

We will use piloted forms developed in Microsoft Excel (Microsoft, Santa Rosa, California, USA) to extract study details (title, author, year of publication, location, setting (hospital/clinic) and source of funding), study design (duration, outcome measure(s), type of sedation used, inclusion and exclusion criteria, sample size and number of endoscopists participating in the trial), participant characteristics (patient demographics, including age, sex and indication for colonoscopy) and intervention characteristics (device or technique, intervention timing and duration).
Intention-to-treat effect estimates and all measures of dispersion will be extracted. Where any study data are missing, authors will be contacted for clarification. All data will be extracted by two independent reviewers. Any disagreements will be resolved through discussion and consensus, involving a third reviewer if necessary.

Outcomes and prioritisation
A preliminary literature review has shown heterogeneity in the types of instruments used to assess the patient experience and there is no existing consensus on how to prioritise measures of patient experience. Therefore, studies reporting any quantitative measure of patient experience, including satisfaction, anxiety, pain or discomfort as an outcome, will be included. Secondary outcomes will include willingness to repeat the procedure, adenoma detection rate, polyp detection rate, caecal intubation rate, caecal intubation time, total colonoscopy time, endoscopist satisfaction, cost in dollars and the occurrence of any adverse events (eg, bleeding and perforation). Studies reporting no outcomes of interest will be excluded.

Patient experience, the primary outcome, will be reported as a continuous outcome expressed as standardised mean difference between treatment and control arms given that we expect heterogeneity in the types of instruments used to assess the patient experience. Secondary outcomes will be expressed as follows: willingness to repeat the procedure will be a binary outcome expressed as relative risk; adenoma detection rate, polyp detection rate, caecal intubation rate and occurrence of adverse events (eg, bleeding and perforation) will be reported as relative risks and cecal intubation time, total colonoscopy time, endoscopist satisfaction and cost will be reported as mean differences.

Quality assessment
Risk of bias for each outcome reported by included studies will be assessed by two independent reviewers using the Cochrane Risk of Bias Tool V.2.0. If sufficient data are available, we will explore heterogeneity in pooled estimates of effect by conducting univariable random-effects meta-regression on critical trial characteristics defined a priori: risk of bias (low vs high/some concerns as classified by the Cochrane Risk of Bias Tool) and study size >100 patients. To identify publication bias resulting from missing studies, funnel plots will be constructed if more than 10 studies are identified for inclusion. Two-sided p<0.05 will indicate statistical significance. Analyses will be performed using Review Manager V.5.0 (Cochrane Collaboration, Oxford, UK) and the meta and metafor packages in RStudio (RStudio, Boston, Massachusetts, USA). Where there are ≤3 studies or studies are too heterogeneous to be quantitatively synthesised, we will conduct a narrative synthesis. Studies incorporated in narrative synthesis will be grouped by the type of intervention that they investigate and qualitatively compared within those groups.

Data synthesis
We will first present a descriptive summary of trial characteristics, including study design, intervention characteristics and participant characteristics. Where ≥3 studies examine a single intervention, we will conduct quantitative synthesis by using pairwise inverse-variance random-effects meta-analysis to estimate the pooled standardised mean difference between the intervention and control for all continuous primary and secondary outcomes and relative risk for binary outcomes. Binary outcomes will also be reported as number needed to treat/harm. If a study arm experiences no events, 0.5 will be added to each cell of the 2×2 table to facilitate synthesis. We will report 95% CIs for all measures of average treatment effect, as well as prediction intervals where appropriate. Studies missing summary data (eg, variance and sample size) will be dealt with on a case-by-case basis to determine if the summary data can be approximated; otherwise, they will be excluded from quantitative synthesis and summarised narratively. In either case, the implications of the missing data will be discussed.

We will use I² scores to quantify heterogeneity, with 0%–25% indicating low heterogeneity, 25%–50% indicating moderate heterogeneity and >50% indicating high heterogeneity. If sufficient data are available, we will explore heterogeneity in pooled estimates of effect by conducting univariable random-effects meta-regression on critical trial characteristics defined a priori: risk of bias (low vs high/some concerns as classified by the Cochrane Risk of Bias Tool) and study size >100 patients. To identify publication bias resulting from missing studies, funnel plots will be constructed if more than 10 studies are identified for inclusion. Two-sided p<0.05 will indicate statistical significance. Analyses will be performed using Review Manager V.5.0 (Cochrane Collaboration, Oxford, UK) and the meta and metafor packages in RStudio (RStudio, Boston, Massachusetts, USA). Where there are ≤3 studies or studies are too heterogeneous to be quantitatively synthesised, we will conduct a narrative synthesis. Studies incorporated in narrative synthesis will be grouped by the type of intervention that they investigate and qualitatively compared within those groups.

CONFIDENCE IN CUMULATIVE EVIDENCE
Two reviewers will independently assess confidence in the cumulative body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for each identified non-pharmacological intervention. Discrepancies will be resolved through discussion and mediation by a third reviewer if necessary. The quality of evidence will be graded as high, medium, low or very low.

ETHICS AND DISSEMINATION
Ethics approval is not required for this study of pre-existing literature.

DISCUSSION
The proposed systematic review will identify and assess non-pharmacological interventions to improve the patient experience of colonoscopy under moderate or no sedation.

This review builds on a previous review by Leung who attempted to describe the breadth of interventions available to endoscopists to improve the patient experience. Leung’s review, while successful at identifying several methods to reduce discomfort during colonoscopy, is of limited applicability to the present context. The review included studies of patients undergoing colonoscopy with deep or moderate sedation, searched only a single database and is now over 10 years old. Other reviews have assessed the effectiveness of specific interventions.
with patient experience as an outcome. However, these have focused on single interventions, and evidence syntheses are absent for many interventions relevant to the study question. In contrast, this contemporary review is designed to search multiple electronic databases, use standardised tools to assess study quality, quantitatively synthesise study results where possible, explores heterogeneity using a pre-specified approach and specifically addresses colonoscopy under moderate/no sedation.

By synthesising the evidence supporting the use of non-pharmacological interventions to improve the patient experience, clinicians may be empowered to look beyond the use of sedatives and analgesics and take a holistic approach to optimising the patient experience of colonoscopy. With patient experience being a key dimension of colonoscopy quality, improving the patient experience of colonoscopy is, in itself, a desirable outcome of synthesising evidence and increasing awareness about non-pharmacological interventions.

Additionally, the findings of our study will be of particular relevance to jurisdictions facing increasing costs of colonoscopy secondary to increased use of deep sedation. One potential driver of deep sedation use is the small patient satisfaction advantage it confers over moderate sedation—synthesising the evidence and raising awareness around non-pharmacological interventions to improve the patient experience may reduce dependence on deep sedation to optimise the patient experience for routine colonoscopy.

Lastly, as the world grapples with the COVID-19 pandemic and many jurisdictions are pausing elective endoscopy, there is the possibility that clinicians may face resource shortages and rationing when elective endoscopy resumes. By synthesising the evidence around options to improve the patient experience of colonoscopy, we may aid clinicians in adapting to these potential resource constraints.

This review has limitations. Some interventions may be evaluated by few studies, and others may be evaluated by studies that are heterogeneous in the outcome measures, patient populations and implementation of the intervention. These challenges may pose barriers to quantitative synthesis. Recognising this, we have pre-specified conditions for conducting quantitative synthesis and methods for exploring heterogeneity. Even if quantitative synthesis is not possible for many interventions, a narrative review will still provide a useful map of the current body of literature supporting non-pharmacological interventions to improve the patient experience of colonoscopy and future directions for research.

REFERENCES
27 Viechtbauer W. Conducting meta-analyses in R with the metafor package 2010.